News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
293,592 Results
Type
Article (14683)
Company Profile (294)
Press Release (278615)
Section
Business (94242)
Career Advice (182)
Deals (14817)
Drug Delivery (31)
Drug Development (51251)
Employer Resources (32)
FDA (6025)
Job Trends (5688)
News (161204)
Policy (10518)
Tag
Academia (982)
Alliances (22520)
Alzheimer's disease (738)
Approvals (5989)
Artificial intelligence (63)
Bankruptcy (103)
Best Places to Work (4990)
Biotechnology (243)
Breast cancer (58)
Cancer (579)
Cardiovascular disease (52)
Career advice (159)
Cell therapy (150)
Clinical research (40415)
Collaboration (210)
Compensation (83)
COVID-19 (1023)
C-suite (53)
Cystic fibrosis (61)
Data (624)
Diabetes (67)
Diagnostics (1593)
Earnings (41041)
Events (58143)
Executive appointments (154)
FDA (6274)
Funding (207)
Gene editing (50)
Gene therapy (127)
GLP-1 (304)
Government (1100)
Healthcare (7433)
Infectious disease (1053)
Inflammatory bowel disease (89)
IPO (8370)
Job creations (919)
Job search strategy (153)
Layoffs (183)
Legal (1440)
Lung cancer (101)
Manufacturing (68)
Medical device (3882)
Medtech (3884)
Mergers & acquisitions (6525)
Metabolic disorders (208)
Neuroscience (919)
NextGen Class of 2024 (2268)
Non-profit (903)
Northern California (856)
Obesity (121)
Opinion (91)
Parkinson's disease (55)
Patents (45)
People (25792)
Pharmaceutical (48)
Phase I (14079)
Phase II (18763)
Phase III (12019)
Pipeline (145)
Postmarket research (901)
Preclinical (5920)
Radiopharmaceuticals (206)
Rare diseases (142)
Real estate (1647)
Regulatory (8571)
Research institute (988)
Southern California (769)
Startups (2052)
United States (7171)
Vaccines (155)
Weight loss (78)
Date
Today (150)
Last 7 days (566)
Last 30 days (1911)
Last 365 days (22366)
2024 (19072)
2023 (24643)
2022 (29472)
2021 (30728)
2020 (26075)
2019 (18436)
2018 (13276)
2017 (15033)
2016 (13198)
2015 (16383)
2014 (11822)
2013 (8532)
2012 (8836)
2011 (9138)
2010 (8739)
Location
Africa (174)
Arizona (46)
Asia (17727)
Australia (2924)
California (1907)
Canada (702)
China (137)
Colorado (65)
Connecticut (76)
Europe (38447)
Florida (217)
Georgia (61)
Illinois (121)
Indiana (61)
Kansas (55)
Maryland (279)
Massachusetts (1607)
Michigan (48)
Minnesota (105)
New Jersey (517)
New York (571)
North Carolina (418)
Northern California (856)
Ohio (77)
Pennsylvania (422)
South America (248)
Southern California (769)
Texas (202)
Washington State (216)
293,592 Results for "arch therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Venture capital
ARCH Fuels Up With $3B to Support Next Class of AI Biotechs
ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to support new startups working with AI.
September 26, 2024
·
1 min read
·
Annalee Armstrong
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
Arch Biopartners Inc. announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for cilastatin, the Company’s second drug candidate for preventing acute kidney injury (AKI).
June 27, 2024
·
5 min read
Press Releases
Arch Biopartners Arranges Non-Brokered Private Placement
October 15, 2024
·
3 min read
Business
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
October 1, 2024
·
5 min read
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (PK) and functional measures with sevasemten (EDG-5506) in adults with Becker.
April 15, 2024
·
12 min read
Press Releases
Endospan Completes Enrollment of Primary Arm in NEXUS® Aortic Arch Stent Graft TRIOMPHE IDE Clinical Study
October 21, 2024
·
2 min read
Genetown
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring) A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster
Arch Therapeutics, Inc. announced that the Company’s first commercial product, AC5® Advanced Wound System, will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting, which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.
May 6, 2024
·
5 min read
Drug Development
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Arch Biopartners Inc. announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
June 18, 2024
·
5 min read
Genetown
Arch Therapeutics Provides Year End Operational Update
Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical products, provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System.
November 9, 2023
·
6 min read
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
Arch Biopartners Inc. announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products (DCRP) on February 23, 2024 to discuss Arch’s plan to repurpose cilastatin as a new treatment to prevent toxin related acute kidney injury (AKI).
February 27, 2024
·
7 min read
1 of 29,360
Next